slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 26,851-26,880
Pages 1,349
Rows per page 30
Beat
26,851-26,880 of 40,452
13
Includes footnotes explaining DCR/LTV calculation and definitions of Metropolitan/Destination/Suburban categories.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Market Size1 hit
14
Hanmi Financial | Results Presentation Deck | 34 slidesHanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Market Size1 hit
15
The slide provides a breakdown of the $962.7 million RRE portfolio as of Dec 31, 2023.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Market Size1 hit
16
The slide uses a donut chart, a horizontal bar chart, and a geographic map to segment the $582.3 million portfolio.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Market Size1 hit
17
Includes a stacked bar chart for deposit mix, a donut chart for personal/business split, and a combo chart for interest-bearing deposit balances and costs.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Market Size1 hit
18
The slide uses a combination of a combo chart (bar/line) and a waterfall chart to explain financial performance.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Financials1 hit
19
Includes three distinct charts showing loan maturity, interest rate trends, and deposit maturity.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Financials1 hit
20
Includes a footnote regarding a one-time gain on a sale-and-leaseback in 3Q23.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Financials1 hit
21
Hanmi Financial | Results Presentation Deck | 34 slidesHanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · Financials1 hit
22
The slide uses a dual-axis approach (line for percentage, stacked bar for absolute dollars) to illustrate asset quality metrics.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
23
The slide uses stacked bar charts to break down asset categories and a line chart for the nonperforming assets/total assets ratio.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
24
The 4Q23 net charge-off figure is negative due to a large recovery.Hanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
25
Hanmi Financial | Results Presentation Deck | 34 slidesHanmi Financial | Results Presentation Deck | 34 slides · Hanmi Financial Corporation
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
24
The slide uses a table structure to organize ESG activities.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · Visualization1 hit
25
HomeStreet | Results Presentation Deck | 36 slidesHomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · VisualizationLoop · Cost Of Inaction1 hit
26
Includes a disclaimer regarding forward-looking statements at the bottom.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · VisualizationLoop · Cost Of Inaction1 hit
19
The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
20
The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
26
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
27
The slide uses a before-and-after visual comparison to illustrate market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
30
The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit